» Articles » PMID: 31737556

Bromelain Inhibitory Effect on Colony Formation: An Study on Human AGS, PC3, and MCF7 Cancer Cells

Overview
Date 2019 Nov 19
PMID 31737556
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Bromelain is dotted with anticancer properties on various cancer cell lines. Anticancer pathways of bromelain, as well related intervening signalization are under investigation. Investigating the inhibitory potential of bromelain on AGS, PC3, and MCF7 cells proliferation and colony formation. The bromelain inhibitory potential on AGS, PC3, and MCF7 cells proliferation at various bromelain concentrations was assessed by MTT; thereby, bromelain potency on colony formation impediment was evaluated using clonogenic assays at determined 50% inhibitory concentrations (IC) on four different cell densities (10, 50, 100, and 200 cells per well). Bromelain inhibits AGS, PC3, and MCF7 cells proliferation in such a dose-dependent manner. Determined IC to AGS, PC3, and MCF7 cells were 65, 60 and 65μg/ml respectively. At IC, bromelain significantly suppressed the AGS, PC3, and MCF7 cells colony formation at four treated densities (10, 50, 100 and 200 cells per well). Plating efficiency percentage and cell surviving fraction were decreased after bromelain treatment to AGS, PC3, and MCF7 human cancer cells as a function of initial cell density. The 50, 50 or 100, and 10 or 50 cells per well were considered to be optimum number of initial cell density for AGS, PC3, and MCF7 cells. Cell proliferative and colony formation inhibition are two pathways to bromelain anticancer effects. The current study displayed a dose-dependent inhibitory effect of bromelain, as well impeding colony formation AGS, PC3, and MCF7 human cancer cells.

Citing Articles

Anticancer Potential of Pineapple and its Bioactive Compound Bromelain.

Kumar D, Suchitra , Mundlia J, Yadav S, Yadav D, Aggarwal N Curr Pharm Des. 2024; 31(6):461-483.

PMID: 39279108 DOI: 10.2174/0113816128303910240713180835.


Synergic Role of Dietary Bioactive Compounds in Breast Cancer Chemoprevention and Combination Therapies.

Mecca M, Sichetti M, Giuseffi M, Giglio E, Sabato C, Sanseverino F Nutrients. 2024; 16(12).

PMID: 38931238 PMC: 11206589. DOI: 10.3390/nu16121883.


Pterostilbene-isothiocyanate reduces miR-21 level by impeding Dicer-mediated processing of pre-miR-21 in 5-fluorouracil and tamoxifen-resistant human breast cancer cell lines.

Kumar V, Haldar S, Saini S, Ghosh S, Dhankhar P, Roy P 3 Biotech. 2023; 13(6):193.

PMID: 37205177 PMC: 10185726. DOI: 10.1007/s13205-023-03582-3.


ACE2-Inhibitory Effects of Bromelain and Ficin in Colon Cancer Cells.

Pakbin B, Dibazar S, Allahyari S, Shariatifar H, Bruck W, Farasat A Medicina (Kaunas). 2023; 59(2).

PMID: 36837502 PMC: 9962737. DOI: 10.3390/medicina59020301.


Anticancer properties of bromelain: State-of-the-art and recent trends.

Pezzani R, Jimenez-Garcia M, Capo X, Sonmez Gurer E, Sharopov F, Lauve Rachel T Front Oncol. 2023; 12:1068778.

PMID: 36698404 PMC: 9869248. DOI: 10.3389/fonc.2022.1068778.


References
1.
Menyhart O, Harami-Papp H, Sukumar S, Schafer R, Magnani L, de Barrios O . Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochim Biophys Acta. 2016; 1866(2):300-319. DOI: 10.1016/j.bbcan.2016.10.002. View

2.
Rafehi H, Orlowski C, Georgiadis G, Ververis K, El-Osta A, Karagiannis T . Clonogenic assay: adherent cells. J Vis Exp. 2011; (49). PMC: 3197314. DOI: 10.3791/2573. View

3.
Dhandayuthapani S, Perez H, Paroulek A, Chinnakkannu P, Kandalam U, Jaffe M . Bromelain-induced apoptosis in GI-101A breast cancer cells. J Med Food. 2011; 15(4):344-9. DOI: 10.1089/jmf.2011.0145. View

4.
Lee A, Oesterreich S, Davidson N . MCF-7 cells--changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015; 107(7). DOI: 10.1093/jnci/djv073. View

5.
Raeisi E, Aghamiri S, Bandi A, Rahmatpour N, Firoozabadi S, Kafi-Abad S . The antitumor efficiency of combined electrochemotherapy and single dose irradiation on a breast cancer tumor model. Radiol Oncol. 2012; 46(3):226-32. PMC: 3472947. DOI: 10.2478/v10019-012-0035-x. View